Solid Biosciences Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Solid Biosciences Inc. (SLDB) reported Adjustments to Additional Paid in Capital, Warrant Issued of $147.10 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-06
- Solid Biosciences Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $147.10M, a 179.72% increase year-over-year.
- Solid Biosciences Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-03-31 was $52.59M, a 267.94% increase year-over-year.
- Solid Biosciences Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2024-03-31 was $14.29M.
- Solid Biosciences Inc. adjustments to additional paid in capital, warrant issued for fiscal 2025 was $52.59M, a 267.94% increase from fiscal 2024.
- Solid Biosciences Inc. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $14.29M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2026-03-31 | $147.10M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $52.59M 10-K · filed 2026-03-19 | |
| 2025-03-31 | $52.59M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $14.29M 10-K · filed 2026-03-19 | |
| 2024-03-31 | $14.29M 10-Q · filed 2025-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |